JAMA Network JAMA Cardiology : Preserving and Promoting Clinical Trial Representativeness
Jul 30, 2025
In this insightful discussion, Roxana Mehran, a leading cardiologist and vice president of the American College of Cardiology, shares her expertise on the importance of clinical trial representativeness. She discusses the challenges of recruiting diverse populations and suggests actionable strategies for enhancing inclusivity in trials. Mehran emphasizes how community engagement and demographic considerations can improve outcomes and trust in clinical research. The conversation highlights the growing role of industry in ensuring that clinical trials reflect the populations they aim to serve.
AI Snips
Chapters
Transcript
Episode notes
Importance of Trial Inclusiveness
- Clinical trials must reflect the diverse patient populations seen in practice to ensure relevant and effective treatments.
- Inclusiveness in trials is crucial to reducing cardiovascular disease burden globally.
Strategies for Inclusive Trial Design
- Design trials with inclusion and exclusion criteria aligned to disease prevalence in different populations.
- Engage communities and tailor recruitment strategies to overcome barriers like language and trust.
Patient and Community Engagement
- Include patient and community representatives on steering committees to build trust and ensure relevant study endpoints.
- Use diverse trial leadership to facilitate better enrollment and analysis for representative results.